Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.
Hideaki BandoYoshiaki NakamuraHiroya TaniguchiManabu ShiozawaHisateru YasuiTaito EsakiYoshinori KagawaTadamichi DendaTaroh SatohKentaro YamazakiYu SunakawaTakeshi KatoMasahiro GotoSatoshi YukiTomohiro NishinaEiji OkiEiji ShinozakiNobuhisa MatsuhashiNaoki TakahashiAkihito TsujiKoushiro OhtsuboMasashi WakabayashiTakashi IkenoMasayuki HataJustin I OdegaardTakayuki YoshinoPublished in: JCO precision oncology (2022)
Patients with lung-only and peritoneum-only metastatic disease have significantly lower levels of ctDNA, suggesting decreased clinical sensitivity for subclonal variants. This observation suggests that such patients may benefit from concurrent tissue and plasma testing to provide optimal genotyping for subsequent therapy selection.
Keyphrases
- circulating tumor
- cell free
- metastatic colorectal cancer
- circulating tumor cells
- end stage renal disease
- squamous cell carcinoma
- small cell lung cancer
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- high throughput
- copy number
- gene expression
- bone marrow
- stem cells
- dna methylation
- mesenchymal stem cells